NeoGenomics’ NGS and MRD Growth Strategy Shines at Morgan Stanley

NeoGenomics Inc. (NEO) emphasized its expanding role in next-generation sequencing (NGS) and molecular residual disease (MRD) testing at Morgan Stanley’s 24th Annual Global Healthcare Conference on September 15, 2026. With a market cap of $2.37 billion and a 127.85% year-over-year stock return, the company is positioning itself to capitalize on a $20 billion MRD market, where its NGS platforms—including RaDaR ST, RaDaR HD, and PanTracer series—are gaining traction. CEO Tony Zook and CFO Abhishek Jain outlined first-half 2026 revenue growth of 26% for NGS, exceeding $250 million annually, while clinical revenue grew about 14%, driven by a 10% share of testing volume but nearly one-third of clinical revenue. Larger panel NGS tests alone saw growth over 20%, underscoring the company’s focus on precision oncology. The Xifin billing system, implemented in Q3 2026, contributed roughly 10% to overall growth, with direct client billing accounting for over 60% of clinical revenue. Medicare coverage for RaDaR ST in immunotherapy indications in August 2026 opened about $4 billion in market access, while margins for NGS and MRD businesses are projected in the mid-60% range. Zook also highlighted a dedicated oncology sales team’s critical mass reached in July 2026, targeting community oncology practices—where 80% of cancer patients seek treatment—with a Net Promoter Score of 78. The company’s portfolio spans nearly 500 tests across solid tumors and hematopathology, and liquid biopsy is expected to become material by late 2027 or 2028. Analysts cite a price target range of $16 to $35, with a Financial Health score of 2.98 (InvestingPro’s ‘GOOD’ rating) and a current ratio of 3.6, reflecting operational stability. Therapy selection penetration in the community remains at 35%–40%, with RaDaR HD’s detection limits down to as low as 1 PPM, furthering its competitive edge in MRD monitoring.